グラクソ・スミスクライン株式会社
Tokyo, Japan
Active| Registration number | T2011001026329 |
|---|---|
| Type | Corporation |
| Registered name | グラクソ・スミスクライン株式会社 |
| Address | 東京都港区赤坂１丁目８番１号 1-8-1 Akasaka, Minato-ku, Tokyo 107-0052, JAPAN |
| Corporate number | 2011001026329 |
| Corporate number assigned on | 2015-10-05 |
| Invoice registered on | 2023-10-01 |
The invoice registration date is when the qualified-invoice-issuer registration (T-number) took effect — it is not the date the company was founded, and it resets only if the business re-registers after revocation or expiry.
Corporate registry record
| Entity type | Kabushiki Kaisha (stock company) |
|---|---|
| Representative | 代表取締役 ポール・リレット |
| Reading (furigana) | グラクソスミスクライン |
| Reading (romaji) | Gurakusosumisukurain |
| English name (unofficial) | Glaxo Smith Klein K.K. |
| Postal code | 107-0052 |
Source: NTA Corporate Number Publication Site, refreshed daily. Representative: gBizINFO (METI, monthly).
Company profile (gBizINFO)
| Business summary | 医療用医薬品の研究開発、輸入、製造、販売 |
|---|---|
| Business lines | E:製造業 |
| Employees | 2,500 （male 1,779 / female 840） |
| Incorporated | 1953-08-18 |
| Website | jp.gsk.com/ja-jp/responsibility/inclusion/ |
Source: gBizINFO (METI), refreshed monthly — edited extract by LoreaTec. Figures are as filed by each company.
Government contract awards (GEPS)
No public national-government (GEPS) award records for this company in the open data (FY2013 to date).
出典：調達ポータル（https://www.p-portal.go.jp/）
Subsidies & grants received (gBizINFO)
2 published awards (2021-11-19 → 2021-11-19, 1 programme, total ¥447.0M).
| 2021-11-19 | 令和３年度（令和２年度からの繰越分）新型コロナウイルス感染症治療薬の実用化のための支援事業費国庫補助金 ¥258.5M （厚生労働省） |
|---|---|
| 2021-11-19 | 令和３年度（令和２年度からの繰越分）新型コロナウイルス感染症治療薬の実用化のための支援事業費国庫補助金 ¥188.5M （厚生労働省） |
Source: gBizINFO (METI) subsidy information, refreshed monthly. Amounts as published (grant decisions). Subsidies database →
Payments from national budget programmes (行政事業レビュー)
Ministry review sheets report this company as a payee of 1 programme (1 lines, sheet years 2024–2024; total ¥442.3M).
| 2024 FY2023 | 新型インフルエンザ等対策費 ¥442.3M （厚生労働省） 医薬品等買上費 |
|---|
Contract details (excerpt): 抗インフルエンザウイルス薬の購入 ¥442.3M・随意契約（その他）
Source: 行政事業レビュー見える化サイト (Cabinet Secretariat, PDL 1.0) — edited extract by LoreaTec. A sheet year describes the previous fiscal year’s spending. Programme database →
Verify in official sources
Doing due diligence on this supplier?
Verifying the invoice number is step one. Our guide covers the full checklist: corporate registry, licenses, and import/export standing.
How to cite this page
Data via LoreaTec BizSearch (https://bizsearch.loreatec.jp/t2011001026329) — Source: National Tax Agency corporate-number and qualified-invoice registries. Retrieved 2026-09-21.
Reusing this page, or answering with it? Paste this line. Training and AI answers are allowed — attribution is the only condition. AI content licence